Novartis makes acquisition to buildout CAR-T capabilities

By Ben Hargreaves

- Last updated on GMT

(Image: Getty/Kritchanut)
(Image: Getty/Kritchanut)

Related tags Novartis CellforCure CAR-T Kymriah

Novartis will acquire French CDMO, CellforCure, to expand its cell and gene therapy manufacturing network.

CellforCure, a contract development and manufacturing organisation (CDMO), owns a manufacturing site in Les Ulis, France. Novartis is set to acquire the organisation from its parent company, LFB, and will add the 3,600m2​ Les Ulis facility to its manufacturing network.

Previously, Novartis had established a deal​ that saw it select CellforCure for the manufacture of its chimeric antigen receptor (CAR)-T treatment, Kymriah (tisagenlecleucel).

Technology transfer between the companies had been completed prior to this latest announcement, with Novartis revealing that it expects production to begin by mid-2019. The facility may be used, however, to boost production in other areas of Novartis’ cell and gene portfolio.

Novartis’ global head of technical operations, Steffen Lang, said in a statement, “The proposed acquisition of CellforCure is another strategic step in our pursuit of additional manufacturing capacity to make our transformational CAR-T cell therapy Kymriah available to more patients in need around the world. If completed, this acquisition also would potentially increase manufacturing capacity for other cell and gene therapies in the Novartis pipeline.”

The move is the latest step Novartis has taken to bolster its internal production capacity for cell and gene therapies. It is also investing CHF90m (€79m) in building a new facility in Stein​, Switzerland, that will also focus on cell and gene therapies – adding 450 new positions over the next three years.

CellforCure is also working with Cellectis to produce an allogeneic CAR-T product, which gained approval to enter clinical trials​ in the US in June of last year.

Novartis noted that it expects the deal to close in the first half of 2019 and would be funded through available cash – though specific cost details were not disclosed.

Related news

Show more

Related products

Trends in Biopharmaceutical Raw Material Selection

Trends in Biopharmaceutical Raw Material Selection

Actylis – The Partner of Choice | 31-Jan-2023 | Business Advice

Join us as our in-house experts, along with Cecile Bellamy from Pfizer, discuss current and future trends in biopharmaceutical raw material selection.

Liposomal and Nanoparticle Technology

Liposomal and Nanoparticle Technology

Pfizer CentreOne | 18-Nov-2022 | Technical / White Paper

Medical science is continuously searching for better ways to administer drugs into the body and to maximize the therapeutic effectiveness of the drugs...

The Reagents Behind Much of Molecular Biology

The Reagents Behind Much of Molecular Biology

Thermo Fisher Scientific | 25-Jul-2022 | Case Study

The ability to amplify, modify and fabricate DNA is fundamental to modern molecular biology. Why do so many researchers take their constituent parts for...

Related suppliers

Follow us


View more